Johnson & Johnson settles talc cancer lawsuits for billions
Consensus Summary
Johnson & Johnson agreed to pay $5.5bn (or $7.9 billion in Australian dollars) to settle approximately 76,000 lawsuits alleging its talc products caused ovarian cancer, covering nearly all remaining claims. The settlement requires 95% of claimants to approve it and excludes future lawsuits, with payments expected to total $3bn in 2027 and additional amounts in 2028, potentially reaching $7bn. The company stopped selling talc-based baby powder in 2020 and faced a three-year pause in litigation after its 'Texas two-step' bankruptcy strategy failed, with three dismissed filings. Payments will be completed within 18 months, faster than previous proposals spread over more than a decade. Both sources agree the deal follows a decade-long legal battle with mixed trial outcomes, including a multi-billion-dollar verdict for 22 women, and J&J’s denial of talc causing cancer.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- $5.5bn settlement announced by Johnson & Johnson to resolve tens of thousands of lawsuits alleging talc products caused ovarian cancer
- Settlement covers about 76,000 claims, including federal and state court cases
- 95% of ovarian cancer claimants must accept the settlement for it to become final
- Johnson & Johnson expects to pay $3bn in 2027, with further payments in 2028
- Settlement could ultimately reach $7bn or more depending on participation
- Company stopped selling talc-based baby powder in the US in 2020, switching to cornstarch
- Litigation resumed in March 2025 after a three-year pause during J&J’s failed 'Texas two-step' bankruptcy strategy
- J&J filed three bankruptcies through a shell-company subsidiary, all dismissed
- Settlement excludes future lawsuits, accelerating payments within 18 months instead of over more than a decade
- J&J previously settled most asbestos/mesothelioma cases but faced mixed verdicts in talc trials, including a $multi-billion verdict for 22 women
- Chris Seeger, representing about 2,500 clients, helped negotiate the agreement
- Erik Haas, J&J’s vice-president of litigation, called claims 'meritless' and said the company would have prevailed in further litigation
Points of Difference
Details reported by only one source:
- ABC reports the settlement as $7.9 billion (equivalent to $US5.5 billion), while Guardian uses $5.5bn as the primary figure
- ABC includes a Reuters photo credit for the headline image (Yves Herman and Mike Segar) not mentioned in Guardian
- Guardian specifies the settlement is a 'landmark deal that could end a contentious, decade-long legal battle' with more emphasis on the 10-year timeline
- Guardian notes J&J won a 'significant court victory last week' when a federal judge cast doubt on plaintiffs’ ability to prove talc caused ovarian cancer
Contradictions
Conflicting information between sources:
- The Guardian states the settlement is worth $5.5bn, while ABC states it is $7.9 billion (equivalent to $US5.5 billion), creating ambiguity about the primary figure
- Guardian mentions 'tens of thousands' of lawsuits but does not explicitly state the number 76,000 in the headline, while ABC does not emphasize the qualitative 'tens of thousands' phrasing
Source Articles
Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit
Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products caused ovarian cancer , in a landmark deal that could end a contentious, decade-long legal battle. Johnson & Johnson on Monday said the settlement covers about 76,000 claims, including ones consolidated in a federal court in New Jersey, and related cases in
US pharma giant to pay out $7.9 billion over baby powder lawsuits
A US pharmaceutical company will pay $7.9 billion to settle thousands of lawsuits that claim its baby powder caused ovarian cancer.